Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis

Journal of Clinical Pharmacology

Volumn 53, Issue 12, 2013, Pages 1240-1251

  Chakraborty, Abhijit ^a   Van, Linh M ^b   Skerjanec, Andrej ^a   Floch, David ^a   Klein, Ulf R ^a   Krammer, Gerhard ^a   Sunkara, Gangadhar ^b   Howard, Dan ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Canakinumab; Gouty arthritis patients; Immunogenicity; Pharmacodynamics; Pharmacokinetics

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; INTERLEUKIN 1BETA; SERUM AMYLOID A; TRIAMCINOLONE ACETONIDE;

ANALGESIA; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; COMORBIDITY; CREATININE CLEARANCE; DISSOCIATION CONSTANT; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GOUT; HUMAN; IMMUNOGENICITY; IN VIVO STUDY; KIDNEY FAILURE; MAXIMUM PLASMA CONCENTRATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

CANAKINUMAB; GOUTY ARTHRITIS PATIENTS; IMMUNOGENICITY; PHARMACODYNAMICS; PHARMACOKINETICS;

ADULT; ANTIBODIES, MONOCLONAL; ARTHRITIS, GOUTY; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; HUMANS; INTERLEUKIN-1BETA; MIDDLE AGED; MODELS, BIOLOGICAL; SERUM AMYLOID A PROTEIN;

EID: 84892951783     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.162     Document Type: Article

References (17)

1. Pope RM, Tschopp J. The role of interleukin1 and the inflammasome in gout: Implications for therapy. Arthritis Rheum. 2007;56(10):3183-3188.
2. So A. Developments in the scientific and clinical understanding of gout. Arthritis Res Ther. 2008;10(5):221.
3. Focosi D, Maggi F, Pistello M, Boggi U, Scatena F. Immunosuppressive monoclonal antibodies: Current and next generation. Clin Microbiol Infect. 2011;17(12):1759-1768.
4. Novartis Pharmaceuticals Corporation. 2012. Ilaris (canakinumab) injection for subcutaneous use [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation.
5. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396-2406.
6. So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficulttotreat gouty arthritis: Results of a multicenter, phase II, doseranging study. Arthritis Rheum. 2010;62(10):3064-3076.
7. Schlesinger N, De Meulemeester M, Pikhlak A, et al. Canakinumab relieves symptoms of acute flares and improves healthrelated quality of life in patients with difficulttotreat gouty arthritis by suppressing inflammation: Results of a randomized, doseranging study. Arthritis Res Ther. 2011;13(2):R53.
8. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: Results from two randomised, multicentre, activecontrolled, doubleblind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839- 1848.
9. Chakraborty A, Tannenbaum S, Rordorf C, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human antiinterleukin 1b monoclonal antibody. Clin Pharmacokinet. 2012;51 (6):e1-e18.
10. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895-900.
11. MireSluis AR, Barrett YC, Devanarayan V, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004;289(1-2):1-16.
12. Shankar G, Devanarayan V, Amaravadi L, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008;48(5):1267-1281.
13. Beal SL, Sheiner LB, Boeckmann AJ. 2009. NONMEM users guide (Version VI). Ellicott City, MD: ICON Development Solutions.
14. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanismbased binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol. 2007;63 (5):548-561.
15. Meibohm B, Zhou H. Characterizing the impact of renal impairment on the clinical pharmacology of biologics. J Clin Pharmacol. 2012;52(1 Suppl):54S-62S.
16. US Department of Health and Human Services, Food and Drug Administration, and Center for Drug Evaluation and Research (CDER). Guidance for Industry: Pharmacokinetics in patients with impaired renal function - study design, data analysis, and impact on dosing and labeling. Food and Drug Administration. http://www.fda. gov/downloads/Drugs/./Guidances/UCM204959.pdf 2010. Accessed May 1, 2013.
17. KuemmerleDeschner JB, Hachulla E, Cartwright R, et al. Twoyear results from an openlabel, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrinassociated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011;70(12):2095-2102.